Glucose conjugation for the specific targeting and treatment of cancer
Open accessThe DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Cancers of diverse origins exhibit marked glucose avidity and high rates of aerobic glycolysis. Increased understanding of this dysfunctional metabolism known as the Warburg effect has led to an interest in targeting it for cancer therapy. One promising strategy for such targeting is glycoconjugation, the linking of a drug to glucose or another sugar. This review summarizes the most salient examples of glycoconjugates, in which known cytotoxins or targeted anticancer therapeutics have been linked to glucose (or another glucose transporter substrate sugar) for improved cancer targeting and selectivity. Building on these examples, this review also provides a series of guidelines for the design and mechanistic evaluation of future glycoconjugates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Today this phenomenon is known as the Warburg effect and is recognized as one of the hallmarks of cancer [3].”
BackgroundWarburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“Almost a century ago, the German scientist Otto Warburg observed that cancerous tissues consume large amounts of glucose compared to non-transformed tissue and have high rates of aerobic glycolysis [1, 2].”
BackgroundThe metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416 · cited 1×
“Almost a century ago, the German scientist Otto Warburg observed that cancerous tissues consume large amounts of glucose compared to non-transformed tissue and have high rates of aerobic glycolysis [1, 2].”
BackgroundTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 1×
“Another antibody-drug conjugate, Kadcyla (trastuzumab emtansine; Figure 2b), received US FDA approval in February 2013 for the treatment of HER2-positive breast cancer following the EMILIA clinical trial [15].”
BackgroundTargeting cancer metabolism: a therapeutic window opens
Vander Heiden, M. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,411 · cited 1×
“Most efforts have focused on using small molecules to inhibit the function of metabolic enzymes, as comprehensively reviewed elsewhere [10, 11].”
BackgroundParker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.026 · Cited by 1,197 · cited 1×
“For this reason, folate receptor α (FR-α) is overexpressed in an estimated 40% of human cancers (it is expressed only by certain types of epithelial cells in healthy individuals) [17, 18].”
BackgroundDe Vivo, D. C., Trifiletti, R. R., Jacobson, R. I., Ronen, G. M., Behmand, R. A., & Harik, S. I. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109053251006 · Cited by 800 · cited 1×
“Incidentally, humans born with a mutated, functionallyimpaired GLUT-1 transporter experience a severe phenotype known as De Vivo disease which results in mental retardation, seizures, and a host of neurological deficits, underscoring the importance of GLUT-1 in supplying glucose to the nervous system [95].”
BackgroundSenter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763 · cited 1×
“Adcertis is thought to enter cancer cells via CD30 receptor-mediated endocytosis and subsequently be trafficked to endosomes, where a combination of degradative enzymes and increased acidity lead to cleavage to the active tubulin inhibitor [14].”
BackgroundGenes of glycolysis are ubiquitously overexpressed in 24 cancer classes
Altenberg, B., & Greulich, K. O. (2004) · Genomics · doi:10.1016/j.ygeno.2004.08.010 · Cited by 659 · cited 1×
“Glycolytic enzymes, as well as the insulinindependent glucose transporter GLUT-1, are widely overexpressed in human cancers [4, 5], and high expression levels of these proteins in tumor biopsy samples correlate with poor cancer prognosis, making them attractive therapeutic targets [6–9].”
BackgroundFolate-targeted therapeutic and imaging agents for cancer
Low, P. S., & Kularatne, S. A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.022 · Cited by 585 · cited 1×
“For this reason, folate receptor α (FR-α) is overexpressed in an estimated 40% of human cancers (it is expressed only by certain types of epithelial cells in healthy individuals) [17, 18].”
Background
Research works printed but not linked: 6
- Herrmann, 2011, Q. J. Nucl. Med. Mol. Imag., 55, 620
- Dosio, 2010, Curr. Opin. Invest. Drugs, 11, 1424
- Palit, 2005, Oncol. Rep., 14, 909
- Stewart, 2008, Oncol. Rep., 20, 1561
- Kerbusch, 2001, Drug Metab. Dispos., 29, 967
- Reske, 1997, J. Nucl. Med., 38, 1344
Cited by
Cu-Catalyzed Click Reaction in Carbohydrate Chemistry
Tiwari, V. K., Mishra, B. B., Mishra, K. B., Mishra, N., Singh, A. S., & Chen, X. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00408 · Cited by 862
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Glycosylation: mechanisms, biological functions and clinical implications
He, M., Zhou, X., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01886-1 · Cited by 499
Cu(I)-Catalyzed Click Chemistry in Glycoscience and Their Diverse Applications
Agrahari, A. K., Bose, P., Jaiswal, M. K., Rajkhowa, S., Singh, A. S., Hotha, S., Mishra, N., & Tiwari, V. K. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00920 · Cited by 472
Metadata
- Authors
- Calvaresi, E. C., & Hergenrother, P. J.
- Affiliations
- University of Illinois Urbana-Champaign (US)
- Corresponding author
- Hergenrother, Paul J.
- Venue
- Chemical Science
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2013
- Volume
- 4
- Issue
- 6
- Pages
- 2319
- ISSN
- 2041-6520 (ISSN-L)
- 2041-6539
- PMC
- PMC3784344
- OpenAlex
- W2110592482
- Cited by
- 398
- References
- 98
- Citations by year
- 2026: 16 · 2025: 42 · 2024: 29 · 2023: 32 · 2022: 41 · 2021: 24 · 2020: 42 · 2019: 43 · 2018: 32 · 2017: 28 · 2016: 40 · 2015: 17 · 2014: 10 · 2013: 2
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Chemical Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- U.S. Food and Drug Administration
- University of Illinois at Urbana-Champaign
- National Cancer Institute (F30CA168323)
- National Institute of General Medical Sciences (R01GM098453)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- glycoconjugates, glucose conjugation, tumor targeting, Warburg effect, aerobic glycolysis, cytotoxin, cancer metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.